Nearly 29% of adults in OASIS 4 who lost at least 10% of their body weight by week 16 on oral semaglutide 25 mg — the pill formulation of Wegovy — went on to reach 21.6% weight loss by week 64. That early-responder signal matters clinically because it hands prescribers a concrete decision point at four months: dose escalation, expectation-setting, and adherence conversations can all be anchored to a measurable threshold rather than intuition.
The physical function data from the same trial deserve equal attention. Among participants with poor baseline physical function, 77.3% on oral semaglutide achieved clinically meaningful improvement in mobility scores — bending, sustained standing, general stamina — versus 42.9% on placebo. That’s not a marginal separation. It’s a near-doubling of responder rate in a subgroup that is both medically high-risk and historically undertreated because injectable therapies carry adherence barriers this population disproportionately faces. A once-daily tablet that produces injectable-class weight loss and functional gains in people who struggle with mobility reframes the access argument entirely.
Novo Nordisk also presented ORION, an indirect treatment comparison showing oral semaglutide produced greater mean weight loss than orforglipron 36 mg, with orforglipron associated with approximately 14-fold higher odds of GI-driven discontinuation. Indirect comparisons carry obvious methodological limitations — different trial populations, protocols, and time horizons — but the framing is deliberate. Eli Lilly’s orforglipron is the most credible oral GLP-1 competitor on the near-term horizon, and Novo Nordisk is building the comparative narrative before head-to-head data exist. The companion OPTIC preference study, showing 84% of respondents favoring a Wegovy-like profile, reinforces that the strategy is as much about shaping prescriber and payer perception as it is about pharmacology.
The regulatory question that will determine whether any of this translates to broad patient access is EMA approval of the oral formulation, still pending. The OASIS 4 dataset is now deep enough — sub-analyses on responder phenotypes, functional endpoints, and tolerability — that the evidentiary package looks complete. Watch the EMA decision timeline: approval in Europe unlocks the market where injectable Wegovy already has traction and where a pill-form label could substantially accelerate uptake without requiring new clinical infrastructure.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
